Case Details
- Citation: [2018] SGHC 149
- Case Title: Millennium Pharmaceuticals, Inc. v Drug Houses of Australia Pte Ltd
- Court: High Court of the Republic of Singapore
- Date of Decision: 27 June 2018
- Procedural Dates: 28 March 2018; 5 April 2018
- Judges: Mavis Chionh Sze Chyi JC
- Suit Number: Suit No 1089 of 2017
- Summonses: Summons No 5611 of 2017; Summons No 5650 of 2017; Summons No 1764 of 2018 (leave to appeal)
- Plaintiff/Applicant: Millennium Pharmaceuticals, Inc.
- Defendant/Respondent: Drug Houses of Australia Pte Ltd
- Legal Areas: Civil Procedure; Injunctions; Pleadings; Patents and Inventions (infringement); Therapeutic product regulatory framework
- Statutes Referenced: Civil Law Act; Medicines Act
- Regulations Referenced: Health Products (Therapeutic Products) Regulations 2016 (S 329/2016) (“TPR”)
- Other Statutory Framework: Health Products Act (Cap 122D, 2008 Rev Ed) (“HPA”); Patents Act (Cap 221, 2005 Rev Ed)
- Patent Details: Plaintiff’s Singapore Patent Nos SG 151322 and SG 182998; expiry 24 March 2025; process patents relating to manufacture of bortezomib
- Therapeutic Product Registration: Defendant’s Therapeutic Product Registration No SIN15243P
- Judgment Length: 48 pages; 15,805 words
- Cases Cited: [2012] SGHC 16; [2018] SGHC 149
Summary
Millennium Pharmaceuticals, Inc. v Drug Houses of Australia Pte Ltd concerned a dispute at the intersection of Singapore’s patent regime and the regulatory process for therapeutic products. The plaintiff, the registered proprietor of two Singapore process patents relating to manufacturing processes for bortezomib (an anti-cancer drug), sued the defendant after the defendant obtained registration for a therapeutic product containing bortezomib. The plaintiff sought declarations that the defendant’s regulatory declarations to the Health Sciences Authority (HSA) were false or misleading in material particulars (or omitted material matters), a declaration of prospective infringement, and an injunction restraining the defendant from infringing the patents.
At the interlocutory stage, the High Court (Mavis Chionh Sze Chyi JC) dismissed the plaintiff’s application for an interlocutory injunction and allowed the defendant’s striking-out application in part. The court’s approach focused on whether the plaintiff had a sufficiently arguable case for the declarations and injunction sought, and whether the pleadings disclosed a reasonable cause of action. The decision also addressed the proper role of the court’s inherent jurisdiction in relation to the regulatory framework and the patent infringement allegations.
What Were the Facts of This Case?
The plaintiff, Millennium Pharmaceuticals, Inc., is incorporated in the United States, while the defendant, Drug Houses of Australia Pte Ltd, is incorporated in Singapore. The plaintiff is the registered proprietor of Singapore Patent Nos SG 151322 and SG 182998. These patents are process patents: they protect certain processes for manufacturing the active ingredient bortezomib rather than the active ingredient itself. The patents were stated to expire on 24 March 2025.
In Singapore, therapeutic products are regulated under the Health Products Act (HPA), with detailed requirements for therapeutic product registration set out in the Health Products (Therapeutic Products) Regulations 2016 (TPR). The HSA evaluates therapeutic products for compliance with statutory requirements relating to quality, safety, efficacy, and presentation, including whether overall intended benefits outweigh overall risks. As part of the registration process, applicants must make declarations on whether a patent is in force in respect of the therapeutic product and, depending on the applicant’s position, whether the applicant is the patent proprietor, whether the proprietor has consented or acquiesced, or whether the applicant believes the patent is invalid or will not be infringed by the acts for which registration is sought.
The defendant obtained approval from the HSA for registration of a therapeutic product described as “Bortezomib – Actavis Powder for Solution for Injection 3.5mg/vial” under Therapeutic Product Registration No SIN15243P on 26 May 2017. The plaintiff alleged that, in obtaining this registration, the defendant omitted to declare the plaintiff’s patents when making the required declarations to the HSA. The plaintiff further alleged that the defendant’s conduct in performing the acts for which registration was obtained would infringe the plaintiff’s process patents.
Crucially, the plaintiff did not manufacture, market, or supply bortezomib in Singapore itself. Instead, it had granted an exclusive licence to Johnson & Johnson Pte Ltd in Singapore. The plaintiff asserted that public hospitals in Singapore conduct annual tenders for bortezomib and that Johnson & Johnson had historically been awarded the tender “by default” because it was the sole participant with an existing therapeutic product registration. The defendant, by obtaining its own therapeutic product registration, was positioned to compete for such tenders.
What Were the Key Legal Issues?
The first cluster of issues concerned the plaintiff’s claims for declarations based on the defendant’s regulatory declarations to the HSA. The plaintiff sought a declaration that the defendant made a declaration containing a statement that was false or misleading in a material particular, or omitted to disclose a matter that was material to its application. This required the court to consider the statutory framework governing therapeutic product registration declarations, including the categories of declarations under the TPR and the consequences of failing to make the appropriate declarations.
A second key issue was whether the plaintiff’s pleadings disclosed a reasonable cause of action, given the defendant’s cross-application to strike out the statement of claim. The court had to determine whether the plaintiff’s infringement-related claims—particularly the prospective infringement declaration claim—were sufficiently pleaded and legally sustainable at the interlocutory stage.
Third, the court had to assess the plaintiff’s interlocutory injunction application. This involved the well-known requirements for granting an injunction: whether there was a serious question to be tried, and whether the balance of convenience favoured granting or refusing the injunction. The court also had to consider how these principles apply in a context where the alleged infringing acts were tied to regulatory registration and subsequent commercial activities.
How Did the Court Analyse the Issues?
The court began by setting out the statutory framework for therapeutic product registration, because the plaintiff’s claims were anchored in the TPR’s declaration regime. Under the HPA and TPR, successful registration indicates that the HSA has evaluated the product for compliance with statutory requirements relating to quality, safety, efficacy, and suitability for intended purpose. The HSA must be satisfied that overall intended benefits outweigh overall risks and that the product is suitable for its intended purpose based on formulation, manufacturing controls, specifications, shelf life, and stability under recommended storage conditions.
Within this framework, the TPR requires applicants to make declarations at the time of application regarding patents in force and the applicant’s relationship to the patent proprietor. The court emphasised that the TPR contemplates different categories of declarations depending on whether a patent is in force and whether the applicant is the proprietor or has consented/acquiesced rights. In particular, the TPR provides for categories A1, A2, A3, and B, each reflecting different patent-related positions. The court also noted that where the applicant is not the proprietor and makes certain declarations (including that the patent is invalid or will not be infringed), the HSA may require the applicant to serve notice on the patent proprietor.
Against this regulatory backdrop, the court addressed the defendant’s striking-out application in Summons No 5650. The court considered two main aspects of the plaintiff’s claims: (i) the “material falsehood declaration” claim and (ii) the “prospective infringement declaration” claim. The court also addressed the plaintiff’s reliance on the court’s inherent jurisdiction, which the plaintiff appeared to invoke to support the availability or scope of the relief sought.
On the material falsehood declaration claim, the court’s analysis turned on whether the plaintiff had properly pleaded that the defendant’s regulatory declaration was false or misleading in a material particular, or omitted a material matter. The court’s reasoning reflected the need to connect the alleged omission to the statutory declaration requirements under the TPR. In other words, the plaintiff could not rely on general assertions; it had to show that the defendant’s declaration regime under the TPR was engaged in a way that made the omission legally material.
On the prospective infringement declaration claim, the court examined the plaintiff’s reliance on Regulation 24(1)(a)(i) of the TPR and the legal consequences of the defendant’s registration. Regulation 24(1)(a)(i) (as discussed in the judgment) was central to the plaintiff’s attempt to obtain a declaration that the defendant’s performance of the acts for which registration was obtained would infringe the plaintiff’s patents. The court also considered whether it was appropriate to grant such prospective relief at the interlocutory stage and whether the pleadings met the threshold for a reasonable cause of action.
In addition, the court considered the plaintiff’s argument that the court should use its inherent jurisdiction to support the relief. The court’s approach indicated that inherent jurisdiction cannot be used to circumvent the statutory scheme or to create a cause of action where the pleaded legal basis is deficient. The court therefore treated inherent jurisdiction as supplementary rather than as a substitute for the statutory requirements underpinning the plaintiff’s claims.
After dealing with the striking-out application, the court turned to the interlocutory injunction application in Summons No 5611. Applying the established test, the court first considered whether there was a serious question to be tried. While the plaintiff had advanced arguments relating to the defendant’s regulatory declarations and the potential for infringement, the court’s earlier findings on the pleadings and the legal basis for the prospective infringement and falsehood declarations affected the assessment of seriousness. The court’s reasoning suggested that where the pleadings are struck out in part, the remaining claims may not be sufficient to establish a serious question for the purposes of an injunction.
The court then considered the balance of convenience. In patent and regulatory disputes, the balance of convenience often involves weighing the potential harm to the plaintiff if the injunction is refused against the potential harm to the defendant (and the public interest) if an injunction is granted. Here, the court dismissed the plaintiff’s interlocutory injunction application. The practical effect was that the defendant was not restrained from performing the acts for which it had obtained registration pending the final determination of the suit.
What Was the Outcome?
The High Court dismissed the plaintiff’s interlocutory injunction application in Summons No 5611. This meant that, pending trial and final resolution, the defendant was not restrained from performing the acts for which it had obtained registration of its therapeutic product.
In Summons No 5650, the court allowed the defendant’s striking-out application in part, striking out certain passages in the plaintiff’s statement of claim. The court’s partial striking-out reduced the scope of the plaintiff’s pleaded case and, in turn, influenced the court’s assessment of the injunction application. The plaintiff was granted leave to appeal against the decision in SUM 5611 via Summons No 1764 of 2018, and the plaintiff appealed against the decisions in both SUM 5611 and SUM 5650.
Why Does This Case Matter?
This decision is significant for practitioners because it clarifies how Singapore courts approach patent-related disputes that arise within the therapeutic product registration framework. The case demonstrates that claims framed around regulatory declarations to the HSA must be carefully tied to the specific statutory declaration obligations and categories under the TPR. Allegations of “false or misleading” statements or material omissions cannot be made in the abstract; they must be pleaded with sufficient legal and factual precision to show materiality within the statutory scheme.
From a civil procedure perspective, the case also illustrates the practical impact of striking-out applications on interlocutory relief. Where pleadings are struck out in part, the remaining claims may no longer support the threshold requirements for an injunction. This reinforces the importance of ensuring that the statement of claim is robust at the pleading stage, particularly in complex regulatory-patent disputes where the court will scrutinise the legal basis for declarations and the availability of prospective relief.
For patent owners and generic or biosimilar entrants, the judgment underscores the strategic and legal consequences of therapeutic product registration declarations. The TPR’s declaration categories and notice mechanisms are not merely administrative formalities; they can become the foundation for litigation. However, the case also signals that courts will not automatically grant broad prospective declarations or injunctive relief simply because a patent exists. The plaintiff must show a legally sustainable cause of action and satisfy the interlocutory requirements.
Legislation Referenced
- Civil Law Act
- Medicines Act
- Health Products Act (Cap 122D, 2008 Rev Ed)
- Health Products (Therapeutic Products) Regulations 2016 (S 329/2016), including Regulation 23 and Regulation 24
- Patents Act (Cap 221, 2005 Rev Ed)
Cases Cited
- [2012] SGHC 16
- [2018] SGHC 149
Source Documents
This article analyses [2018] SGHC 149 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.